British Journal of Cancer · 2008 · 41 citations · 23 references
MedicineCancer BiologyOncologyBreast OncologyEndocrine OncologyMolecular OncologyBreast Cancer OncologyEndocrine Tumor PathologyEndocrine Tumor PrognosisHormonal Cancer TherapyImmuno-oncology BiomarkersMalignant NeoplasmsBreast Cancer PrognosisEndocrine ResistanceHormone Receptor - Positive Breast CancerKaplan-meier Confidence IntervalsKaplan-meier Survival EstimatesMicroarray AnalysisProgesterone Receptor StatusTissue Microarray Analysis
Elevated c-Src protein expression has been shown in breast cancer and in vitro evidence suggests a role in endocrine resistance. To investigate whether c-Src is involved in endocrine resistance, we examined the expression of both total and activated c-Src in human breast cancer specimens from a cohort of oestrogen receptor (ER)-positive tamoxifen-treated breast cancer patients. Tissue microarray technology was employed to analyse 262 tumour specimens taken before tamoxifen treatment. Immunohistochemistry using total c-Src and activated c-Src antibodies was performed. Kaplan-Meier survival curves were constructed and log-rank test were performed. High level of nuclear activated Src was significantly associated with improved overall survival (P=0.047) and lower recurrence rates on tamoxifen (P=0.02). Improved patient outcome was only seen with activated Src in the nucleus. Nuclear activated Src expression was significantly associated with node-negative disease and a lower NPI (P<0.05). On subgroup analysis, only ER-positive/progesterone receptor (PgR)-positive tumours were associated with improved survival (P=0.004). This shows that c-Src activity is increased in breast cancer and that activated Src within the nucleus of ER-positive tumours predicts an improved outcome. In ER/PgR-positive disease, activated Src kinase does not appear to be involved in de novo endocrine resistance. Further study is required in ER-negative breast cancer as this may represent a cohort in which it is associated with poor outcome.
23
Tamoxifen for early breast cancer: an overview of the randomised trials
The Lancet · 1998 · 4.1K citations
McCarty Ks, Éva Szabó, Flowers Jl et al. · PubMed · 1986 · 422 citations
Medicine, Endocrinology, Oncology +17
Richard S. Finn, Judy Dering, Charles Ginther et al. · Breast Cancer Research and Treatment · 2007 · 403 citations · Full text